Brain Efflux Index To Investigate the Influence of Active Efflux on Brain Distribution of Pemetrexed and Methotrexate

Antifolates, in particular methotrexate (MTX), have been widely used in the treatment of primary and secondary tumors of the central nervous system (CNS). Pemetrexed (PMX) is a novel antifolate that also exhibits potent antitumor activity against CNS malignancies. Studies have shown that brain distribution of both antifolates is significantly restricted, possible due to active efflux transport at the blood-brain barrier (BBB). This study characterizes the brain-to-blood transport of PMX and MTX and examines the role of several efflux transporters in brain distribution of the antifolates by use of the intracerebral microinjection technique (brain efflux index). The results from this study show that both PMX and MTX undergo saturable efflux transport across the BBB, with elimination half-lives of approximately 39 minutes and 29 minutes, respectively. Of the various efflux transporters this study investigated, multidrug resistance-associated protein 2 (Mrp2) does not play an important role in the brain distribution of the two antifolate drugs. Interestingly, breast-cancer resistance protein (Bcrp) makes a significant contribution to the brain elimination of MTX but not PMX. In addition, the brain-to-blood transport of both antifolates was inhibited by probenecid and benzylpenicillin, suggesting the involvement of organic anion transporters in the efflux of these compounds from the brain, with organic anion transporter 3 (Oat3) being a possibility. Our results suggest that one of the underlying mechanisms behind the limited brain distribution of PMX and MTX is active efflux transport processes at the BBB, including a benzylpenicillin-sensitive transport system and/or the active transporter Bcrp.

[1]  Li Li,et al.  pH-Dependent Transport of Pemetrexed by Breast Cancer Resistance Protein , 2011, Drug Metabolism and Disposition.

[2]  P. Wen,et al.  Survival among patients with primary central nervous system lymphoma, 1973–2004 , 2011, Journal of Neuro-Oncology.

[3]  R. Kim,et al.  Blood−brain barrier transporters and response to CNS-active drugs , 2009, European Journal of Clinical Pharmacology.

[4]  Y. Sugiyama,et al.  Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs , 2009, Expert opinion on drug metabolism & toxicology.

[5]  O. van Tellingen,et al.  Functionally Overlapping Roles of Abcg2 (Bcrp1) and Abcc2 (Mrp2) in the Elimination of Methotrexate and Its Main Toxic Metabolite 7-Hydroxymethotrexate In vivo , 2009, Clinical Cancer Research.

[6]  T. Batchelor,et al.  LONG-TERM OUTCOME IN PCNSL PATIENTS TREATED WITH HIGH-DOSE METHOTREXATE AND DEFERRED RADIATION , 2008, Neurology.

[7]  Thomas J. Raub,et al.  Roles of P-Glycoprotein, Bcrp, and Mrp2 in Biliary Excretion of Spiramycin in Mice , 2007, Antimicrobial Agents and Chemotherapy.

[8]  H. Pospisil,et al.  In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression , 2007, Investigational New Drugs.

[9]  T. Fukami,et al.  P-glycoprotein mediates brain-to-blood efflux transport of buprenorphine across the blood–brain barrier , 2007, Journal of drug targeting.

[10]  F. Russel,et al.  Interaction of Nonsteroidal Anti-Inflammatory Drugs with Multidrug Resistance Protein (MRP) 2/ABCC2- and MRP4/ABCC4-Mediated Methotrexate Transport , 2007, Journal of Pharmacology and Experimental Therapeutics.

[11]  T. Terasaki,et al.  Functional characterization of the brain-to-blood efflux clearance of human amyloid-β peptide (1–40) across the rat blood–brain barrier , 2006, Neuroscience Research.

[12]  J. Schellens,et al.  Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice , 2006, Journal of Pharmacology and Experimental Therapeutics.

[13]  L. Recht,et al.  Optimizing therapy for patients with brain metastases. , 2006, Seminars in oncology.

[14]  W. Elmquist,et al.  Distribution of the Novel Antifolate Pemetrexed to the Brain , 2005, Journal of Pharmacology and Experimental Therapeutics.

[15]  P. Wielinga,et al.  Mrp4 Confers Resistance to Topotecan and Protects the Brain from Chemotherapy , 2004, Molecular and Cellular Biology.

[16]  Tetsuya Terasaki,et al.  Organic anion transporter 3 is involved in the brain‐to‐blood efflux transport of thiopurine nucleobase analogs , 2004, Journal of neurochemistry.

[17]  S. Cole,et al.  The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. , 2004, Current drug metabolism.

[18]  E. L. Volk,et al.  Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. , 2003, Cancer research.

[19]  P. L. Golden,et al.  Blood-brain barrier efflux transport. , 2003, Journal of pharmaceutical sciences.

[20]  H. Kusuhara,et al.  Contribution of Organic Anion Transporter 3 (Slc22a8) to the Elimination of p-Aminohippuric Acid and Benzylpenicillin across the Blood-Brain Barrier , 2003, Journal of Pharmacology and Experimental Therapeutics.

[21]  H. Takanaga,et al.  Rat Organic Anion Transporter 3 (rOAT3) is Responsible for Brain-to-Blood Efflux of Homovanillic Acid at the Abluminal Membrane of Brain Capillary Endothelial Cells , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  H. Takanaga,et al.  Role of blood–brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain , 2002, Journal of neurochemistry.

[23]  M. Kuwano,et al.  Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. , 2002, Cancer research.

[24]  Y. Sugiyama,et al.  In vivo evidence for brain-to-blood efflux transport of valproic acid across the blood-brain barrier. , 2002, Microvascular research.

[25]  T. Abe,et al.  Characterization of the Efflux Transport of 17β-Estradiol-d-17β-glucuronide from the Brain across the Blood-Brain Barrier , 2001 .

[26]  Q. Smith,et al.  Characterization of the blood–brain barrier choline transporter using the in situ rat brain perfusion technique , 2001, Journal of neurochemistry.

[27]  J. Drewe,et al.  Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. , 2000, Molecular pharmacology.

[28]  R. Evers,et al.  Interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. , 2000, Molecular pharmacology.

[29]  H. Kusuhara,et al.  Molecular Cloning and Characterization of a New Multispecific Organic Anion Transporter from Rat Brain* , 1999, The Journal of Biological Chemistry.

[30]  H. Kusuhara,et al.  P-Glycoprotein mediates the efflux of quinidine across the blood-brain barrier. , 1997, The Journal of pharmacology and experimental therapeutics.

[31]  B A Telfer,et al.  Tissue water content in rats measured by desiccation. , 1997, Journal of pharmacological and toxicological methods.

[32]  Y. Sugiyama,et al.  In vivo evidence for carrier-mediated efflux transport of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. , 1997, The Journal of pharmacology and experimental therapeutics.

[33]  Y. Sugiyama,et al.  Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier. , 1996, The Journal of pharmacology and experimental therapeutics.

[34]  H. Kusuhara,et al.  Active efflux across the blood-brain barrier: Role of the solute carrier family , 2011, NeuroRX.

[35]  J. Olson,et al.  Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study , 2008, Journal of Neuro-Oncology.

[36]  A. Klein-Szanto,et al.  Multidrug resistance protein 4 protects bone marrow, thymus, spleen, and intestine from nucleotide analogue-induced damage. , 2007, Cancer research.

[37]  C. Waters,et al.  Pharmacokinetic Considerations in the Treatment of CNS Tumours , 2006, Clinical pharmacokinetics.

[38]  H. Kusuhara,et al.  Brain efflux index method. Characterization of efflux transport across the blood-brain barrier. , 2003, Methods in molecular medicine.

[39]  H. Kusuhara,et al.  Brain Efflux Index Method , 2003 .

[40]  W. Pardridge.  Crossing the blood-brain barrier: are we getting it right? , 2001, Drug discovery today.

[41]  T. Abe,et al.  Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood-brain barrier. , 2001, The Journal of pharmacology and experimental therapeutics.

[42]  W. Pardridge.  Blood-brain barrier biology and methodology. , 1999, Journal of neurovirology.

[43]  J. Gallo,et al.  In vivo microdialysis to characterize drug transport in brain tumors: analysis of methotrexate uptake in rat glioma-2 (RG-2)-Bearing rats , 1996, Cancer Chemotherapy and Pharmacology.